Marketing Promises CBD Companies Have Paid to Make: A Look at FDA Warning Letters and What They Mean for Consumers

If you have spent any time browsing CBD products online, you have almost certainly encountered language suggesting that a particular tincture, gummy, or topical can address a specific health condition. Words like "relieves," "treats," "cures," and "prevents" appear with remarkable frequency in an industry whose products have not, with rare exception, received FDA approval to make such claims.

This is not a gray area. The FDA has established clear boundaries around what dietary supplement and food product manufacturers—categories under which most CBD products currently fall—are permitted to say in their marketing. And the agency, alongside the Federal Trade Commission, has documented its enforcement efforts in a public record that consumers can and should find instructive.

The Regulatory Framework: What the FDA Actually Permits

Under the Federal Food, Drug, and Cosmetic Act, a product that claims to diagnose, cure, treat, mitigate, or prevent a disease is legally classified as a drug—regardless of whether it is sold in a wellness store or marketed as a "natural" supplement. CBD products sold without FDA drug approval cannot legally make these claims.

What manufacturers can say falls into a narrower category: structure/function claims. These are statements about how a nutrient or ingredient may support normal bodily processes or general well-being, rather than addressing a specific disease. Examples include language like "supports a sense of calm," "may promote restful sleep," or "formulated for everyday wellness." Even these claims carry requirements: they must be truthful, substantiated, and accompanied by a disclaimer stating the FDA has not evaluated the claim and the product is not intended to diagnose, treat, cure, or prevent any disease.

The line between a structure/function claim and an illegal disease claim is not always intuitively obvious to consumers—which is, arguably, part of the problem.

What the Warning Letters Reveal

Since 2019, the FDA has issued a substantial number of warning letters specifically targeting CBD companies. Reviewing them collectively reveals recurring patterns in the types of violations documented.

Cancer-related claims appear with troubling frequency. Multiple companies have been cited for marketing CBD products as treatments for or preventatives against various forms of cancer. One warning letter documented a company's website describing CBD as able to "kill cancer cells" and "stop the spread of cancer"—language that is not only legally prohibited but scientifically unsupported for any commercial CBD product currently on the market.

Alzheimer's disease and neurological conditions have also featured prominently. Companies have been cited for claiming their products could slow the progression of Alzheimer's, treat epilepsy outside the context of the FDA-approved drug Epidiolex, or address other serious neurological disorders. The distinction matters: Epidiolex is an FDA-approved pharmaceutical containing a purified form of CBD, approved for specific seizure disorders following rigorous clinical trials. Over-the-counter CBD products have not undergone that process and cannot make equivalent claims.

Mental health conditions represent another category where enforcement has been active. Claims that CBD products treat depression, PTSD, or anxiety disorders—as opposed to supporting general relaxation or mood balance—cross into disease claim territory and have been cited accordingly.

COVID-19 generated a specific wave of enforcement activity beginning in 2020, when some CBD companies began marketing their products as preventatives or treatments for the virus. The FDA and FTC issued joint warning letters to several companies, noting that no CBD product had been demonstrated to prevent, treat, or cure COVID-19 and that such claims posed a direct public health risk by potentially discouraging consumers from seeking proven interventions.

The FTC's Role: When Marketing Becomes Deception

While the FDA focuses on product labeling and drug claim violations, the Federal Trade Commission has jurisdiction over advertising more broadly—including claims made on websites, in social media, and in promotional materials. The FTC's standard is that advertising must be truthful and substantiated by competent and reliable scientific evidence.

In practice, this means that even claims that technically avoid disease language can still attract FTC scrutiny if they are misleading or unsupported. Testimonials claiming dramatic health outcomes, implied medical endorsements, and before-and-after framing have all appeared in FTC actions against CBD companies.

The FTC's Operation CBDeceit, launched in 2020, resulted in warning letters to companies making what the agency described as "unsubstantiated claims" about CBD's effectiveness for a range of conditions. The operation signaled that both agencies were coordinating their oversight of the space—and that enforcement was not merely theoretical.

Why This Matters to Consumers: Recognizing the Pattern

Enforcement actions are instructive not only for the companies that receive them but for consumers trying to evaluate the marketplace. The marketing patterns that have drawn regulatory attention are not limited to the companies that were caught. They represent a widespread approach to CBD advertising that exploits consumer interest in natural health solutions and the genuine early-stage science around cannabinoids.

Here is what that pattern typically looks like in practice:

• Anecdote-forward advertising: Testimonials from customers describing dramatic recoveries or cures are used to imply clinical efficacy without making a direct claim. The FTC has specifically noted that testimonials must reflect typical results and cannot be used to substantiate claims that are not otherwise supported.

• Scientific language without scientific rigor: Phrases like "clinically shown" or "research-backed" appear without citation to peer-reviewed studies—or with citations to preliminary research that does not support the strength of the claim being made.

• Condition-specific product naming: Products named "Anxiety Relief," "Pain Away," or "Sleep Cure" are using their product titles to make implicit disease claims while keeping the formal label language technically compliant. Regulators have taken notice of this approach.

• Doctor or expert endorsements: Some companies feature medical professionals in their marketing in ways that imply clinical validation. Unless those professionals have conducted legitimate clinical research on the specific product, this framing can be misleading.

What Early Research Does and Doesn't Support

None of this is to suggest that CBD is without potential. The scientific literature on cannabidiol is genuinely developing, and there are areas—anxiety, sleep quality, certain pain pathways, and inflammation—where preliminary research is promising enough to warrant continued investigation. The approval of Epidiolex demonstrates that at least one highly refined CBD-based pharmaceutical has met the FDA's rigorous efficacy and safety standards for specific conditions.

The problem is not the science. The problem is the gap between what early-stage research suggests and what marketing language asserts. A study showing that CBD reduced anxiety scores in a small sample of participants with social anxiety disorder is not equivalent evidence to a product claiming to "eliminate anxiety." Consumers deserve to understand that distinction, and reputable companies communicate it honestly.

How to Apply This Knowledge When Evaluating Products

A practical takeaway from reviewing FDA warning letters and FTC enforcement actions is this: the specific language a company uses in its marketing is itself a quality signal. Companies that stay within compliant, appropriately hedged language are demonstrating regulatory awareness. Those making sweeping health claims—regardless of how compelling those claims sound—are either uninformed about the rules or willing to disregard them for commercial gain.

When evaluating a CBD brand, consider the following:

• Does the company use disease-specific language ("treats," "cures," "prevents") for conditions beyond what the FDA has approved?
• Are testimonials used to imply clinical outcomes without appropriate disclaimers?
• Does the product name itself suggest a specific medical application?
• Is cited research accurately represented, or does the marketing overstate what studies actually found?

The FDA's warning letter database is publicly accessible at fda.gov, and searching for CBD-related letters provides a useful reference point for both specific companies and the broader patterns of violation. Informed consumers who understand the regulatory framework are better equipped to read marketing critically—and to place greater confidence in brands that operate within it.